Rheumatology

Evidence supporting a novel therapeutic target for systemic lupus erythematosus (SLE), the E3 ubiquitin ligase “E3-X”, was presented at ACR Convergence 2024 in Washington, D.C.

Researchers unveiled a groundbreaking study shedding light on the complex molecular interplay driving fibrosis in diffuse systemic sclerosis (dcSSc) at ACR 2024 in Washington, D.C., USA.

New research into how antisynthetase autoantibodies disrupt critical enzymatic functions in muscle cells was presented as part of a plenary abstract session at ACR Convergence 2024 in Washington, D.C.

Participation in the Rheumatology Informatics System for Effectiveness (RISE), an electronic heath record (EHR)-enabled registry designed by the American College of Rheumatology (ACR), significantly improves clinical care metrics, according to a study presented at ACR Convergence 2024.

A Phase III clinical trial presented at ACR Convergence 2024 revealed that upadacitinib (UPA), combined with a 26-week glucocorticoid (GC) improved disease control and reduced steroid exposure compared to a placebo (PBO) regimen in patients with giant cell arteritis (GCA).

Presented at the ACR Convergence 2024, new research highlighted how changing global recruitment patterns influence placebo response rates in clinical trials for psoriatic arthritis (PsA).

In a groundbreaking study, once-weekly semaglutide injections were shown to significantly reduce both knee osteoarthritis pain and body weight in adults with obesity, offering promising new relief for patients with limited treatment options.

Recent findings have underscored the role of traumatic stress as a potent trigger for autoimmune rheumatic diseases (ARDs), emphasizing a feedback loop that perpetuates these conditions.